Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops

NCT06969001 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Wet Age Related Macular Degeneration

Interventions

DRUG: SCAI-005 0.04% or placebo
DRUG: SCAI-005 0.08% or placebo
DRUG: SCAI-005 0.08% or placebo 2drops

Sponsor

SCAI Therapeutics